- Home
- PRQR vs FHTX Comparison
PRQR vs FHTX Comparison
Compare PRQR & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- FHTX
- Stock Information
- Founded
- PRQR 2012
- FHTX 2015
- Country
- PRQR Netherlands
- FHTX United States
- Employees
- PRQR N/A
- FHTX N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- PRQR Health Care
- FHTX Health Care
- Exchange
- PRQR Nasdaq
- FHTX Nasdaq
- Market Cap
- PRQR 232.8M
- FHTX 278.1M
- IPO Year
- PRQR 2014
- FHTX 2020
- Fundamental
- Price
- PRQR $2.25
- FHTX $5.06
- Analyst Decision
- PRQR Strong Buy
- FHTX Strong Buy
- Analyst Count
- PRQR 8
- FHTX 6
- Target Price
- PRQR $8.88
- FHTX $11.33
- AVG Volume (30 Days)
- PRQR 319.5K
- FHTX 87.3K
- Earning Date
- PRQR 08-07-2025
- FHTX 08-05-2025
- Dividend Yield
- PRQR N/A
- FHTX N/A
- EPS Growth
- PRQR N/A
- FHTX N/A
- EPS
- PRQR N/A
- FHTX N/A
- Revenue
- PRQR $20,129,184.00
- FHTX $24,173,000.00
- Revenue This Year
- PRQR N/A
- FHTX $43.75
- Revenue Next Year
- PRQR N/A
- FHTX $1.27
- P/E Ratio
- PRQR N/A
- FHTX N/A
- Revenue Growth
- PRQR 8.65
- FHTX N/A
- 52 Week Low
- PRQR $1.07
- FHTX $2.95
- 52 Week High
- PRQR $4.62
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- PRQR 57.03
- FHTX 47.33
- Support Level
- PRQR $2.18
- FHTX $5.16
- Resistance Level
- PRQR $2.33
- FHTX $5.63
- Average True Range (ATR)
- PRQR 0.13
- FHTX 0.35
- MACD
- PRQR 0.02
- FHTX 0.01
- Stochastic Oscillator
- PRQR 84.91
- FHTX 38.83
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.